Juan José Badimon (Juan Badimon, Juan J Badimon, Juan Jose Badimon)

Loop profile ORCID

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 20

Top Venues

Cardiovascular drugs and therapy

Journal of cardiovascular development and disease

International journal of molecular sciences

Circulation. Cardiovascular imaging

Icahn School of Medicine at Mount Sinai

University of Barcelona (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Icahn School of Medicine at Mount Sinai Jul 01 2007

United States

Professor Medicine/Cardiology :: Cardiovascular Institute

Education History

University of Barcelona

Spain

PHD :: Pharmacy/Biochemistry

Publications

Vanessa Roldan, Juan José Badimon
Does One Size Fits All? Cardiovascular drugs and therapy (2024)
Carlos A Gongora, Lili Zhang, Juan Lopez Mattei, Enrique Ruiz-Mori, Gina Gonzalez-Robledo, Leandro Slipczuk, Joffre Lara, Jorge E Cossio-Aranda, Juan José Badimon
Are Sodium-Glucose Cotransporter-2 Inhibitors the Cherry on Top of Cardio-Oncology Care? Cardiovascular drugs and therapy (2024)
Maeve Soto Pérez, Jorge Rodríguez-Capitán, Juan Antonio Requena-Ibáñez, Carlos G Santos-Gallego, M Urooj Zafar, Ginés Escolar, Donna Mancini, Sumeet Mitter, David Lam, Johanna P Contreras, Icilma Fergus, Farah Atallah-Lajam, Vivian Abascal, Anu Lala, Pedro Moreno, Noah Moss, Stamatios Lerakis, Javier Sanz, Valentin Fuster, Juan José Badimon
Rationale and Design of the SOTA-P-CARDIA Trial (ATRU-V): Sotagliflozin in HFpEF Patients Without Diabetes. Cardiovascular drugs and therapy (2023)
Ariana P Vargas-Delgado, Estefania Arteaga Herrera, Cesar Tumbaco Mite, Patricia Delgado Cedeno, Maria Cristina Van Loon, Juan José Badimon
Renal and Cardiovascular Metabolic Impact Caused by Ketogenesis of the SGLT2 Inhibitors. International journal of molecular sciences 24 (4) (2023)
Ariana P Vargas-Delgado, Estefania Arteaga Herrera, Cesar Tumbaco Mite, Patricia Delgado Cedeno, Maria Cristina Van Loon, Juan José Badimon
Renal and Cardiovascular Metabolic Impact Caused by Ketogenesis of the SGLT2 Inhibitors. International journal of molecular sciences 24 (4) (2023)
Carlos G Santos-Gallego, Juan Antonio Requena-Ibáñez, Belen Picatoste, Brian Fardman, Kiyotake Ishikawa, Renata Mazurek, Michael Pieper, Samantha Sartori, Jorge Rodríguez-Capitán, Valentin Fuster, Juan José Badimon
Cardioprotective Effect of Empagliflozin and Circulating Ketone Bodies During Acute Myocardial Infarction. Circulation. Cardiovascular imaging (2023)
Ariana P Vargas-Delgado, Estefania Arteaga Herrera, Cesar Tumbaco Mite, Patricia Delgado Cedeno, Maria Cristina Van Loon, Juan José Badimon
Renal and Cardiovascular Metabolic Impact Caused by Ketogenesis of the SGLT2 Inhibitors. International journal of molecular sciences 24 (4) (2023)
Ariana P Vargas-Delgado, Estefania Arteaga Herrera, Cesar Tumbaco Mite, Patricia Delgado Cedeno, Maria Cristina Van Loon, Juan José Badimon
Renal and Cardiovascular Metabolic Impact Caused by Ketogenesis of the SGLT2 Inhibitors. International journal of molecular sciences 24 (4) (2023)
Juan José Badimon, Gines Escolar, M Urooj Zafar
Factor XI/XIa Inhibition: The Arsenal in Development for a New Therapeutic Target in Cardio- and Cerebrovascular Disease. Journal of cardiovascular development and disease 9 (12) (2022)
Carlos G Santos-Gallego, Manuel Mayr, Juan José Badimon
SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism. Circulation 146 (11) (2022)
Carlos G Santos-Gallego, Juan Antonio Requena-Ibanez, Juan José Badimon
Per-Protocol Versus Intention-to-Treat in Clinical Trials: The Example of GLOBAL-LEADERS Trial. Journal of the American Heart Association 11 (10) (2022)
Juan José Badimon, Gines Escolar, M Urooj Zafar
Factor XI/XIa Inhibition: The Arsenal in Development for a New Therapeutic Target in Cardio- and Cerebrovascular Disease. Journal of cardiovascular development and disease 9 (12) (2022)
Juan José Badimon, Gines Escolar, M Urooj Zafar
Factor XI/XIa Inhibition: The Arsenal in Development for a New Therapeutic Target in Cardio- and Cerebrovascular Disease. Journal of cardiovascular development and disease 9 (12) (2022)
Juan José Badimon, Gines Escolar, M Urooj Zafar
Factor XI/XIa Inhibition: The Arsenal in Development for a New Therapeutic Target in Cardio- and Cerebrovascular Disease. Journal of cardiovascular development and disease 9 (12) (2022)
Juan José Badimon, Gines Escolar, M Urooj Zafar
Factor XI/XIa Inhibition: The Arsenal in Development for a New Therapeutic Target in Cardio- and Cerebrovascular Disease. Journal of cardiovascular development and disease 9 (12) (2022)
Juan Antonio Requena-Ibáñez, Carlos G Santos-Gallego, Anderly Rodriguez-Cordero, M Urooj Zafar, Juan José Badimon
Prolyl Hydroxylase Inhibitors: a New Opportunity in Renal and Myocardial Protection. Cardiovascular drugs and therapy (2021)
Eduardo Flores, Carlos G Santos-Gallego, Nely Diaz-Mejía, Juan José Badimon
Do the SGLT-2 Inhibitors Offer More than Hypoglycemic Activity? Cardiovascular drugs and therapy 32 (2) (2019)
Carlos G Santos-Gallego, Alvaro Garcia-Ropero, Donna Mancini, Sean P Pinney, Johanna P Contreras, Icilma Fergus, Vivian Abascal, Pedro Moreno, Farah Atallah-Lajam, Ronald Tamler, Anu Lala, Javier Sanz, Valentin Fuster, Juan José Badimon
Rationale and Design of the EMPA-TROPISM Trial (ATRU-4): Are the "Cardiac Benefits" of Empagliflozin Independent of its Hypoglycemic Activity? Cardiovascular drugs and therapy 33 (1) (2019)
Meagan P O'Brien, M Urooj Zafar, Jose C Rodriguez, Ibeawuchi Okoroafor, Alex Heyison, Karen Cavanagh, Gabriela Rodriguez-Caprio, Alan Weinberg, Gines Escolar, Judith A Aberg, Juan José Badimon
Targeting thrombogenicity and inflammation in chronic HIV infection. Science advances 5 (6) (2019)
Álvaro García-Ropero, Ariana P Vargas-Delgado, Carlos G Santos-Gallego, Juan José Badimon
Inhibition of Sodium Glucose Cotransporters Improves Cardiac Performance. International journal of molecular sciences 20 (13) (2019)

Juan José Badimon.css-eqlu8i{font-size:small;padding-left:4px;} (Juan Badimon, Juan J Badimon, Juan Jose Badimon)

Publication Activity (10 Years)

Top Topics

Top Venues

Juan José Badimon (Juan Badimon, Juan J Badimon, Juan Jose Badimon)